Itepekimab Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving Itepekimab Growth

(1) Large COPD market opportunity with high unmet need

COPD remains one of the largest respiratory markets globally. According to WHO, COPD causes ~3.5 million deaths annually and remains the third leading cause of death worldwide. Many patients continue to experience exacerbations despite triple inhaled therapy (ICS/LABA/LAMA), creating significant demand for biologics.

The commercial opportunity became more visible after Dupixent (also co-developed by Sanofi/Regeneron) received FDA approval for COPD in 2024, validating payer and physician willingness to adopt biologics in this market. Reuters noted that Dupixent generated €10.7 billion in 2023 sales, and Sanofi expects it could exceed €22 billion by 2030, highlighting how large respiratory immunology franchises can become.

(2) First IL-33 inhibitor to generate late-stage COPD efficacy data

Itepekimab targets IL-33, an upstream epithelial cytokine involved in broad inflammatory pathways across COPD phenotypes. This gives it potential advantages over eosinophil-focused biologics that only treat narrower subsets.

In the Phase III AERIFY-1 trial (n=1,127), itepekimab achieved a 27% reduction in moderate/severe COPD exacerbations at week 52 vs placebo, meeting its primary endpoint. This was one of the strongest validations of IL-33 biology in COPD prior to AstraZeneca's later success with tozorakimab.

(3) Broad patient eligibility (former smokers regardless of eosinophil count)

A major commercial advantage is broader patient eligibility. Unlike IL-4/IL-13 or IL-5 biologics that primarily target eosinophilic COPD patients, itepekimab demonstrated benefit in former smokers regardless of eosinophilic phenotype, potentially expanding its addressable market.

This could help it reach patients who are not eligible for currently approved biologics.

(4) Favorable safety profile supports long-term adoption

Sanofi and Regeneron reported that adverse events were generally comparable to placebo across both Phase III studies.

• AEs: 67-68% vs 68% placebo (AERIFY-1)
• Serious infections: 7% vs 10% placebo
• Death-related AEs: 1% vs 2% placebo

Strong tolerability is critical in chronic respiratory diseases where long-term biologic use is common.

Itepekimab Recent Developments

In May 2025, The AERIFY-1 Phase III study evaluating itepekimab in former smokers with inadequately controlled chronic obstructive pulmonary disease (COPD) met the primary endpoint of a statistically significant reduction in moderate or severe acute exacerbations compared to placebo of 27% at week 52, a clinically meaningful benefit. The AERIFY-2 Phase III study did not meet the same primary endpoint, although a benefit was seen earlier in the trial.

"Itepekimab Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of Itepekimab for potential indication like Chronic obstructive pulmonary disease and Rhinosinusitis in the 7MM. A detailed picture of Itepekimab's existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the Itepekimab for potential indications. The Itepekimab market report provides insights about Itepekimab's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Itepekimab performance, future market assessments inclusive of the Itepekimab market forecast analysis for potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Itepekimab sales forecasts, along with factors driving its market.

Itepekimab Drug Summary

Itepekimab is an investigational fully human monoclonal antibody developed by Regeneron Pharmaceuticals in collaboration with Sanofi that targets Interleukin-33, an upstream epithelial alarmin involved in initiating airway inflammation. By binding to IL-33 and preventing its interaction with the ST2 receptor, itepekimab inhibits downstream inflammatory cascades linked to both type 2 and non-type 2 respiratory inflammation. The drug is primarily being developed for Chronic Obstructive Pulmonary Disease and has also been evaluated in Asthma. Clinical studies have shown promising reductions in COPD exacerbations-particularly in former smokers-highlighting its potential as a first-in-class biologic for a disease area with limited biologic treatment options. Itepekimab remains in late-stage clinical development and represents a novel upstream anti-inflammatory approach in respiratory medicine. The report provides Itepekimab's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Itepekimab Market Report

The report provides insights into:

• A comprehensive product overview including the Itepekimab MoA, description, dosage and administration, research and development activities in potential indication like Chronic obstructive pulmonary disease and Rhinosinusitis.
• Elaborated details on Itepekimab regulatory milestones and other development activities have been provided in Itepekimab market report.
• The report also highlights Itepekimab's cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The Itepekimab market report also covers the patents information, generic entry and impact on cost cut.
• The Itepekimab market report contains current and forecasted Itepekimab sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Itepekimab market report also features the SWOT analysis with analyst views for Itepekimab in potential indications.

Methodology:

The Itepekimab market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Itepekimab Analytical Perspective by DelveInsight

• In-depth Itepekimab Market Assessment

This Itepekimab sales market forecast report provides a detailed market assessment of Itepekimab for potential indication like Chronic obstructive pulmonary disease and Rhinosinusitis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Itepekimab sales data uptil 2034.

• Itepekimab Clinical Assessment

The Itepekimab market report provides the clinical trials information of Itepekimab for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Itepekimab Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Itepekimab Market Potential & Revenue Forecast

• Projected market size for the Itepekimab and its key indications
• Estimated Itepekimab sales potential (Itepekimab peak sales forecasts)
• Itepekimab Pricing strategies and reimbursement landscape

Itepekimab Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Itepekimab Market positioning compared to existing treatments
• Itepekimab Strengths & weaknesses relative to competitors

Itepekimab Regulatory & Commercial Milestones

• Itepekimab Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Itepekimab Clinical Differentiation

• Itepekimab Efficacy & safety advantages over existing drugs
• Itepekimab Unique selling points

Itepekimab Market Report Highlights

• In the coming years, the Itepekimab market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Itepekimab companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Itepekimab's dominance.
• Other emerging products for Chronic obstructive pulmonary disease and Rhinosinusitis are expected to give tough market competition to Itepekimab and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Itepekimab in potential indications.
• Analyse Itepekimab cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Itepekimab sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Itepekimab in potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of Itepekimab? How strong is Itepekimab's clinical and commercial performance?
• What is Itepekimab's clinical trial status in each individual indications such as Chronic obstructive pulmonary disease and Rhinosinusitis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Itepekimab Manufacturers?
• What are the key designations that have been granted to Itepekimab for potential indications? How are they going to impact Itepekimab's penetration in various geographies?
• What is the current and forecasted Itepekimab market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Itepekimab in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Itepekimab for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is Itepekimab? What is the duration of therapy and what are the geographical variations in cost per patient?